Research

Hormonal

PPAR agonists (specifically pioglitazone) improve individual histological features of NASH (steatosis, ballooning, inflammation) and can improve fibrosis.

Pioglitazone, a PPAR agonist, improves liver inflammation and fat in NASH patients. It is taken orally (30-45 mg daily). A significant side effect is weight gain (~2.5 kg), which might be undesirable for obese patients. It can also improve fibrosis.

GoodSupportsHIGH confidence
Pioglitazone... improved individual histological features of NASH (eg, steatosis, ballooning, lobular inflammation)... mild improvement in liver fibrosis
Peter Y. W. Chan et al. · JBJS Reviews · 2024

Why this rating

Based on 8 RCTs including pioglitazone.

Source

Glucagon-like Peptide-1 Agonists

Peter Y. W. Chan et al. · JBJS Reviews · 2024

DOI 10.2106/jbjs.rvw.23.00167

systematic_review · n=2597Cited 14×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →